APA (7th ed.) Citation

Lorenzen, S., Schwarz, A., Pauligk, C., Goekkurt, E., Stocker, G., Knorrenschild, J. R., . . . Al-Batran, S. (2023). Ramucirumab plus irinotecan / leucovorin / 5-FU versus ramucirumab plus paclitaxel in patients with advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction, who failed one prior line of palliative chemotherapy: The phase II/III RAMIRIS study (AIO-STO-0415). BMC Cancer, 23(1), 1. https://doi.org/10.1186/s12885-023-11004-z

Chicago Style (17th ed.) Citation

Lorenzen, Sylvie, et al. "Ramucirumab Plus Irinotecan / Leucovorin / 5-FU Versus Ramucirumab Plus Paclitaxel in Patients with Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction, Who Failed One Prior Line of Palliative Chemotherapy: The Phase II/III RAMIRIS Study (AIO-STO-0415)." BMC Cancer 23, no. 1 (2023): 1. https://doi.org/10.1186/s12885-023-11004-z.

MLA (9th ed.) Citation

Lorenzen, Sylvie, et al. "Ramucirumab Plus Irinotecan / Leucovorin / 5-FU Versus Ramucirumab Plus Paclitaxel in Patients with Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction, Who Failed One Prior Line of Palliative Chemotherapy: The Phase II/III RAMIRIS Study (AIO-STO-0415)." BMC Cancer, vol. 23, no. 1, 2023, p. 1, https://doi.org/10.1186/s12885-023-11004-z.